173 related articles for article (PubMed ID: 25752393)
1. Molecular imaging biomarkers of resistance to radiation therapy for spontaneous nasal tumors in canines.
Bradshaw TJ; Bowen SR; Deveau MA; Kubicek L; White P; Bentzen SM; Chappell RJ; Forrest LJ; Jeraj R
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):787-95. PubMed ID: 25752393
[TBL] [Abstract][Full Text] [Related]
2. Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.
Bradshaw TJ; Yip S; Jallow N; Forrest LJ; Jeraj R
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):399-405. PubMed ID: 24685446
[TBL] [Abstract][Full Text] [Related]
3. Predicting location of recurrence using FDG, FLT, and Cu-ATSM PET in canine sinonasal tumors treated with radiotherapy.
Bradshaw T; Fu R; Bowen S; Zhu J; Forrest L; Jeraj R
Phys Med Biol; 2015 Jul; 60(13):5211-24. PubMed ID: 26083082
[TBL] [Abstract][Full Text] [Related]
4. Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study.
Bowen SR; Chappell RJ; Bentzen SM; Deveau MA; Forrest LJ; Jeraj R
Radiother Oncol; 2012 Oct; 105(1):41-8. PubMed ID: 22682748
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.
Bradshaw TJ; Bowen SR; Jallow N; Forrest LJ; Jeraj R
J Nucl Med; 2013 Nov; 54(11):1931-7. PubMed ID: 24042031
[TBL] [Abstract][Full Text] [Related]
6. Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study.
Clausen MM; Hansen AE; Lundemann M; Hollensen C; Pommer T; Munck Af Rosenschöld P; Kristensen AT; Kjær A; McEvoy FJ; Engelholm SA
Radiat Oncol; 2014 Oct; 9():228. PubMed ID: 25319766
[TBL] [Abstract][Full Text] [Related]
7. Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT.
Hansen AE; Kristensen AT; Law I; McEvoy FJ; Kjær A; Engelholm SA
Radiother Oncol; 2012 Mar; 102(3):424-8. PubMed ID: 22119225
[TBL] [Abstract][Full Text] [Related]
8. Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus.
Han D; Yu J; Yu Y; Zhang G; Zhong X; Lu J; Yin Y; Fu Z; Mu D; Zhang B; He W; Huo Z; Liu X; Kong L; Zhao S; Sun X
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1235-41. PubMed ID: 19910143
[TBL] [Abstract][Full Text] [Related]
9. Different distribution of (62) Cu ATSM and (18)F-FDG in head and neck cancers.
Kositwattanarerk A; Oh M; Kudo T; Kiyono Y; Mori T; Kimura Y; Maruyama R; Fujibayashi Y; Fujieda S; Okazawa H
Clin Nucl Med; 2012 Mar; 37(3):252-7. PubMed ID: 22310251
[TBL] [Abstract][Full Text] [Related]
10. Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx.
Nyflot MJ; Harari PM; Yip S; Perlman SB; Jeraj R
Radiother Oncol; 2012 Oct; 105(1):36-40. PubMed ID: 23068711
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study.
Clausen MM; Hansen AE; Af Rosenschold PM; Kjaer A; Kristensen AT; McEvoy FJ; Engelholm SA
Radiat Oncol; 2013 Nov; 8():262. PubMed ID: 24199939
[TBL] [Abstract][Full Text] [Related]
12. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
[TBL] [Abstract][Full Text] [Related]
13. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
14. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
15. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.
Dehdashti F; Grigsby PW; Mintun MA; Lewis JS; Siegel BA; Welch MJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1233-8. PubMed ID: 12654432
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?
Kendi AT; Corey A; Magliocca KR; Nickleach DC; Galt J; Switchenko JM; El-Deiry MW; Wadsworth JT; Hudgins PA; Saba NF; Schuster DM
Eur J Radiol; 2015 Jun; 84(6):1171-6. PubMed ID: 25816993
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of tumoral heterogeneity and volumetric parameters as measured by F18-FDG PET/CT in sinonasal cancer.
Kim BS; Pak K; Yi KI; Kim IJ; Roh HJ; Cho KS
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1437-1443. PubMed ID: 27747383
[TBL] [Abstract][Full Text] [Related]
18. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
[TBL] [Abstract][Full Text] [Related]
19. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
Dietz DW; Dehdashti F; Grigsby PW; Malyapa RS; Myerson RJ; Picus J; Ritter J; Lewis JS; Welch MJ; Siegel BA
Dis Colon Rectum; 2008 Nov; 51(11):1641-8. PubMed ID: 18682881
[TBL] [Abstract][Full Text] [Related]
20. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
